Udvalget fandt, at fordelene ved Xagrid opvejer risiciene som andetvalgsbehandling af udsatte patienter med essentiel trombocytæmi.
They decided that Xagrid’ s benefits are greater than its risks as second-line treatment in at risk patients with essential thrombocythaemia.